Bard Implanted Port Catheters (MDL 3081): What the Record Shows

The Bard implanted port catheter litigation is a federal multidistrict proceeding, MDL No. 3081, before Senior Judge David G. Campbell in the District of Arizona. It consolidates federal product liability actions that allege Bard manufactured the catheter component of its implanted ports with a concentration of barium sulfate that was too high, reducing the material’s integrity and leading to infection, catheter fracture, catheter migration or thrombosis. The Judicial Panel on Multidistrict Litigation created the proceeding by a transfer order filed August 8, 2023. The Panel’s report dated October 1, 2026 lists 4,140 actions pending out of 4,420 filed. No ruling on the merits of the barium sulfate allegation appears in the documents reviewed for this article.

What an implanted port catheter is

An implanted port sits under the skin and provides repeated access to the bloodstream. FDA classifies it under product code LJT, “Port & Catheter, Implanted, Subcutaneous, Intravascular.” The classification record describes a “subcutaneous, implanted, intravascular infusion port and catheter,” places it in Class II, lists regulation number 880.5965 and marks it as an implanted device. Class II devices in this category are reviewed through the 510(k) premarket notification pathway.

FDA records identify specific Bard products. Bard Access Systems received clearance for the PowerPort isp, PowerPort Slim, PowerPort M.R.I. and PowerPort M.R.I. isp ports under K251253, decided June 18, 2025 as “Substantially Equivalent.” K050310 covered the BardPort Titanium Ports, decided April 18, 2005 with the same decision. A PowerPort isp recall entry describes the device as “indicated for patient therapies requiring repeated access to the vascular system for the infusion of medications, I.V. fluids, parenteral nutrition solutions.”

What the transfer order says

The order records ten actions pending in six districts and 38 potential tag-along actions in 25 districts. The defendants it names are Becton, Dickinson & Co., C.R. Bard, Inc. and Bard Access Systems, Inc. Plaintiffs asked for the Western District of Missouri. The defendants opposed centralization or suggested the District of Utah or the District of Arizona.

The Panel chose Arizona, noting that a constituent action was pending there, that Bard Access Systems has a significant business presence in the district, that relevant witnesses would be located there and that Judge Campbell presides over MDL No. 2641, the Bard IVC filter litigation involving a different device.

The order states the common factual question: allegations that the defendants “manufacture the catheter component of their port devices with a concentration of barium sulfate that is too high, which reduces the material integrity of the catheter, and can lead to injuries, including infection, fracture of the catheter, migration of the catheter, and thrombosis.” It also lists common issues about testing, adverse-event monitoring and reporting.

The defendants argued that individual issues would predominate and that many filed cases were meritless. The Panel rejected those arguments as a basis for denying centralization. That ruling was about procedure, not the merits of any claim.

What is established vs. what is alleged

Established by the documents reviewed: the existence of MDL No. 3081; the date and terms of the transfer order; the transferee court and judge; the defendants named in the order; the initial action count; the pending and filed counts as of October 1, 2026; FDA’s device classification; the 510(k) clearances; two Class 2 recalls unrelated to barium sulfate; and the bellwether schedule.

Alleged, and not decided: that the catheter component was manufactured with too high a concentration of barium sulfate; that this reduced the material integrity of the catheter; and that it caused infection, fracture, migration or thrombosis in any patient. The Panel recorded those assertions as the plaintiffs’ contentions. A transfer order summarizes allegations to explain why cases belong together. It does not adopt them.

Where the claims stand procedurally

The Panel’s October 1, 2026 report records 4,140 actions pending and 4,420 filed. The same date’s docket summary identifies the master docket as 2:23-md-3081, with a date filed of May 24, 2023 and a transfer date of August 8, 2023.

The court has scheduled a bellwether trial. First Amended Case Management Order No. 50, signed September 24, 2026, states that “A jury trial in the Hicks bellwether case is set to begin on December 1, 2026.” It sets a final pretrial conference for October 26, 2026 in Phoenix and requires a proposed final pretrial order by October 20, 2026. It also refers to the trial held in Cook v. Becton Dickinson and Company, et al., No. 2:23-cv-01975, which it treats as prior trial experience in the same MDL. The order does not state the outcome of that trial, and this article does not either.

A bellwether trial is a test case selected from a group of similar claims. Its result can inform how the parties litigate the remaining cases, but it does not decide them. An MDL is also not a class action. Under 28 U.S.C. § 1407, actions are consolidated for pretrial proceedings before one judge, and each plaintiff keeps an individual claim unless a class is certified or a settlement resolves the claims together. Background appears in MDLs compared with class actions.

What the FDA record shows

The FDA records reviewed for this article contain no action addressing the barium sulfate allegation. They do contain two Class 2 recalls of Bard implantable ports for other reasons.

The first, Z-1300-2014, covered the PowerPort Slim Implantable Port. The recall was initiated on February 27, 2014 and posted on March 27, 2014. The reason given is a labeling discrepancy: the label stated that the port contained silicone suture plugs, while approximately 23 percent of the units in the affected lots had a PowerPort Slim titanium port without them. The record lists the recall as terminated on September 5, 2014.

The second, Z-1525-2010, covered the Titanium PowerPort isp Implanted Port with a 6 French Chronoflex polyurethane catheter. It was initiated on March 18, 2010 and posted on April 29, 2010 because “8F PowerPort stems were mixed with 6F PowerPorts and packaged.” It was terminated on October 1, 2010.

Both are Class 2 recalls. Neither describes barium sulfate concentration as the reason. A recall is a regulatory action about a specific product and problem, not a court finding that a device caused an injury.

Key dates

• April 18, 2005: FDA clears the BardPort Titanium Ports under K050310 as substantially equivalent (510(k) record).
• March 18, 2010: Bard Access Systems initiates the Z-1525-2010 recall after 8 French stems were mixed with 6 French ports (FDA recall record).
• February 27, 2014: Bard Access Systems initiates the Z-1300-2014 recall over a labeling discrepancy about silicone suture plugs (FDA recall record).
• May 24, 2023: the Panel’s docket summary records the date filed for MDL No. 3081 (JPML docket summary).
• August 8, 2023: the Panel files the transfer order creating MDL No. 3081 and assigns it to Judge David G. Campbell (JPML transfer order).
• June 18, 2025: FDA clears the PowerPort isp, PowerPort Slim and PowerPort M.R.I. ports under K251253 (510(k) record).
• September 24, 2026: the court signs First Amended Case Management Order No. 50, setting the Hicks bellwether trial for December 1, 2026 (court order).
• October 1, 2026: the Panel records 4,140 actions pending out of 4,420 filed (JPML statistics report).
• October 26, 2026: final pretrial conference scheduled in the Hicks bellwether case (court order).

What this does not establish

Nothing reviewed here shows a court finding that a Bard port catheter caused any injury, that barium sulfate was present in an excessive concentration, or that any defendant did anything unlawful. The recalls described above concern labeling and product mix, not the barium sulfate allegation, and a recall does not establish that any person was harmed. No settlement approval, trial verdict or admission of liability appears in the documents reviewed. The scheduled trial date is a court deadline, not a prediction of any outcome. A pending-case count measures filings, not merit.

Frequently asked questions

Is there a Bard implanted port catheter settlement?

No settlement approval appears in the documents reviewed for this article. MDL No. 3081 remains in pretrial proceedings, and the most recent court document reviewed here sets a bellwether trial for December 1, 2026 rather than announcing a resolution.

Which companies are defendants in the MDL?

The transfer order names Becton, Dickinson & Co., C.R. Bard, Inc. and Bard Access Systems, Inc. FDA records identify Bard Access Systems as the applicant for the port clearances cited in this article.

Has the FDA recalled Bard ports because of barium sulfate?

No such recall appears in the documents reviewed here. The Bard port recalls found in FDA’s device recall records concern a labeling discrepancy about suture plugs and a mix of 8 French and 6 French stems. An allegation in a lawsuit and an FDA regulatory action are separate things.

What happens next in the litigation?

The court has scheduled a final pretrial conference for October 26, 2026 and a jury trial in the Hicks bellwether case for December 1, 2026. Court schedules can change, and readers can check the docket in the District of Arizona for current dates. The wider device picture appears in the medical device litigation hub, including the separate AngioDynamics port catheter litigation and the Bard IVC filter litigation.

Sources

1. United States Judicial Panel on Multidistrict Litigation: “Transfer Order, In re Bard Implanted Port Catheter Products Liability Litigation, MDL No. 3081” (link, accessed 2026-10-19)
2. United States Judicial Panel on Multidistrict Litigation: “MDL Statistics Report - Distribution of Pending MDL Dockets by Actions Pending, Report Date 10/1/2026” (link, accessed 2026-10-19)
3. United States Judicial Panel on Multidistrict Litigation: “MDL Statistics Report - Docket Summary Listing by MDL Number, Report Date 10/1/2026” (link, accessed 2026-10-19)
4. U.S. Food and Drug Administration: “Product Classification: Port & Catheter, Implanted, Subcutaneous, Intravascular (Product Code LJT)” (link, accessed 2026-10-19)
5. U.S. Food and Drug Administration: “510(k) Premarket Notification K251253: PowerPort Implantable Ports” (link, accessed 2026-10-19)
6. U.S. Food and Drug Administration: “510(k) Premarket Notification K050310: BardPort Titanium Ports” (link, accessed 2026-10-19)
7. U.S. Food and Drug Administration: “Class 2 Device Recall Z-1300-2014: PowerPort Slim Implantable Port” (link, accessed 2026-10-19)
8. U.S. Food and Drug Administration: “Class 2 Device Recall Z-1525-2010: Titanium PowerPort isp Implanted Port” (link, accessed 2026-10-19)
9. United States District Court for the District of Arizona: “First Amended Case Management Order No. 50, In re Bard Implanted Port Catheter Products Liability Litigation, No. 2:23-md-03081 (D. Ariz., filed Sept. 24, 2026)” (link, accessed 2026-10-19)

CollectiveClaim.us publishes general legal information. This article is not legal advice and does not create an attorney–client relationship. Court records and agency actions change; verify current status with the court or agency before relying on it.